Announcements Trials
Browse Landscape

Phase

Phase 1 7Phase NA 1Phase EARLY_PHASE1 1Phase 3 1Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 80Breast Neoplasms 52Prostatic Neoplasms 42Lung Neoplasms 29Multiple Myeloma 28Parkinson Disease 4, Autosomal Dominant Lewy Body 22Neoplasms 21Neoplasm Metastasis 20Leukemia, Lymphocytic, Chronic, B-Cell 19Colorectal Neoplasms 19Carcinoma, Renal Cell 19Ovarian Neoplasms 17Squamous Cell Carcinoma of Head and Neck 13Recurrence 12Leukemia, Myeloid, Acute 12Urinary Bladder Neoplasms 11Small Cell Lung Carcinoma 11Pancreatic Neoplasms 11Myasthenia Gravis 11Endometrial Neoplasms 11Triple Negative Breast Neoplasms 10Stomach Neoplasms 9Non-Muscle Invasive Bladder Neoplasms 9Nasopharyngeal Carcinoma 9Lymphoma, Large B-Cell, Diffuse 9Fallopian Tube Neoplasms 9Lymphoma, Non-Hodgkin 8Lymphoma, Follicular 8Carcinoma 8Burkitt Lymphoma 8

Interventions

Temozolomide 1Radiation 1Photons 1Magnetic Resonance Spectroscopy 1Lomustine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Gliosarcoma × 30 days × Clear all
NCT05095376 2026-05-19

Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma

NRG Oncology

Phase 3 Active not recruiting
265 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡